Biomedical subjects

S Tikanoja

Publications and source records attributed to S Tikanoja.

22 records · Page 2Linked to original sources

PubMedDate not supplied

Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.

Serum CA M26 and CA M29 values were determined in 125 women: 46 patients with primary breast cancer, 49 patients with benign breast disease, and 30 controls. The mean CA M26 and CA M29 values in breast cancer patients were higher than in patients with benign breast disease and in control subjects. When we set the cut-off level at 40 kU/1 for CA M26, 15/46 (33%) of all breast cancer patients, 11/20 (55%) of breast cancer patients with axillary node involvement, 1/1 breast cancer patient with distant metastases, 4/49 (8%) of patients with benign breast disease, and 7/30 (23%) of control subjects were above this cut-off level. For comparison, at the cut-off level of 10 kU/1 the CA M29 test was positive in 30/46 (65%) cancer cases, in 16/20 (80%) of cancer patients with nodal involvement, in 9/49 (18%) of the patients with benign breast disease, and in 10/30 (33%) of control subjects. Patients with axillary nodal metastasis showed higher values than patients without metastasis in both tests. When we used a cut-off level of 15 kU/1 for CA M29, 24% (11/46) of all breast cancer patients, 35% (7/20) of breast cancer patients with axillary node involvement, 4% (2/49) of patients with benign breast disease, and 0% of control subjects were above this cut-off level. The combination of CA M26 at the 40 kU/l cut-off level and CA M29 at the 10 kU/l cut-off level reached the diagnostic sensitivity of 0.65, specificity of 0.78, and efficiency of 0.72. In breast cancer detection among patients with breast problems serum marker CA M29 reached the sensitivity of 0.65 at the specificity level of 0.82. Our results suggest that the CA M29 marker alone is as good as the panel of two markers (CA M26, CA M29) in breast cancer diagnostics. Thus it seems that CA M29 is a promising serum tumor marker in breast cancer.

Adult↗

PubMedDate not supplied

Efficient test for cancer antigens: decreased levels of cancer antigen in serum after excision of breast tumor.

Monoclonal antibody technology has developed new serum marker tests which may offer advantages in the follow up of cancer patients. In breast cancer detection among symptomatic patients MCA and CA 15-3 monoclonals at best reach a sensitivity of about 0.45 at a specificity level of 0.90. We have tested these monoclonal tests (MCA and CA 15-3) by applying them to detect the postoperative decrease of marker levels in the serum among women with breast cancer or benign breast disease. The CA 15-3 postoperative decrease test (5% decrease) reached slightly higher diagnostic sensitivity (0.70) and efficiency (0.83) than the MCA postoperative decrease test (sensitivity 0.65, efficiency 0.80). The combined MCA and CA 15-3 decrease tests had a sensitivity of 0.85 and an efficiency of 0.90 at 5% decrease level. The postoperative decrease test is far superior to normal marker tests in breast cancer detection, especially when several sensitive markers are used. A 35% or larger decrease in serum levels of MCA or CA 15-3 after surgery was 100% specific for breast cancer, and detected 43% of all cancer cases. Although such a test cannot be used for screening, it could be valuable in special diagnostic situations.

Antibodies, Monoclonal↗

PubMedDate not supplied

A new tumor marker MCA in breast cancer diagnosis.

The serum concentration of the new tumor marker MCA (mucinous carcinoma associated antigen) was determined by an enzyme immunoassay kit method, which is based on the use of a monoclonal antibody b12. The mean MCA values in breast cancer patients (n = 40) were significantly higher than in patients with benign breast disease (n = 55, p less than 0.001) and in control subjects (n = 37, p less than 0.001). When we used the cut-off level 11 KU/l for MCA, 6/37 (16.2%) of control subjects 7/55 (12.7%) of patients with benign breast disease, 18/40 (45.0%) of all breast cancer patients 11/19 (57.9%) of breast cancer patients with axillary node involvement, and 1/1 breast cancer patient with distant metastases were above this cut-off level. For comparison, at the cut-off level of 5 micrograms/l the CEA test was positive in 7/40 (18%) cancer cases, and in 6/19 (32%) of cancer patients with nodal involvement. Patients with axillary nodal metastasis showed higher values than patients without metastasis in both tests (p less than 0.01). The combination of MCA at 11 KU/l cut-off level and CEA at the 5.0 micrograms/l cut-off level reached the diagnostic sensitivity of 0.53, efficiency of 0.73, and specificity of 0.87. It seems that MCA is a promising tumor marker in breast cancer. Especially high values may have diagnostic significance.

Adult↗

PubMedDate not supplied

Total and lipid-bound serum sialic acid in benign and malignant breast disease.

Elevation in the total sialic acid (TSA), TSA/total protein (TSA/TP) and lipid-bound sialic acid (LASA) concentration in serum occurs in breast cancer and we have studied the applicability of the assays in classification of undefined breast tumors. Sialic acid was determined by HPLC and the statistical evaluation included the receiver operating characteristic (ROC) and Youden's index analyses. In cancer patients, the serum LASA and TSA concentration was significantly higher (p < 0.05) than in patients with benign breast disease and all the markers were significantly higher (p < 0.0001) than in normal controls. All the markers had a low accuracy (AUCs < 0.75) in differentiating between breast cancer and benign breast disease and at the specificity level of 0.95 the corresponding sensitivities were 0.32 (TSA), 0.14 (TSA/TP) and 0.23 (LASA). The results indicate that both breast cancer and benign breast disease cause elevation of TSA, TSA/TP and LASA values in serum and do not provide reliable classification of undefined breast tumors.

Adolescent↗